NCI Drug Dictionary

The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.

Browse:
anti-HER2 monoclonal antibody/anti-CD137 anticalin bispecific fusion protein PRS-343
A bivalent, bispecific fusion protein comprised of an anti-human epidermal growth factor receptor (HER2) monoclonal antibody linked to a CD137-targeting anticalin with potential immunostimulatory and antineoplastic activities. Upon administration of anti-HER2 monoclonal antibody/anti-CD137 anticalin bispecific fusion protein PRS-343, CD137 clustering is promoted by bridging CD137-positive T cells with HER2-positive tumor cells, leading to the recruitment of tumor antigen-specific cytotoxic T lymphocytes (CTLs). This may result in potent CTL-mediated lysis of HER2-expressing tumor cells. HER2 plays a key role in tumor cell proliferation and tumor vascularization. CD137 is a costimulatory immunoreceptor and a member of the tumor necrosis factor receptor superfamily (TNFRSF). Anticalins are synthetic antigen-binding proteins derived from lipocalins. Structurally dissimilar to antibodies, anticalins are able to bind to smaller antigens and exhibit improved tissue penetration. Check for active clinical trials using this agent. (NCI Thesaurus)

Code name:PRS-343